{
    "2020-09-04": [
        [
            {
                "time": "",
                "original_text": "长春高新：控股子公司金妥利珠单抗注射液获药物临床试验批准",
                "features": {
                    "keywords": [
                        "长春高新",
                        "金妥利珠单抗注射液",
                        "药物临床试验",
                        "批准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "长春高新(000661.SZ)：金妥利珠单抗注射液获批开展血液系统恶性肿瘤、晚期恶性实体瘤和淋巴瘤的临床试验",
                "features": {
                    "keywords": [
                        "长春高新",
                        "金妥利珠单抗注射液",
                        "临床试验",
                        "血液系统恶性肿瘤",
                        "晚期恶性实体瘤",
                        "淋巴瘤"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2020-09",
                "original_text": "医药行业2020年9月投资月报：建议关注IVD化学发光赛道 业绩高增长可期",
                "features": {
                    "keywords": [
                        "医药行业",
                        "IVD化学发光",
                        "投资月报",
                        "业绩高增长"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "生长激素龙头长春高新上半年净利增长超8成，不断丰富产品线布局下半年业绩增长有望加速丨领航100",
                "features": {
                    "keywords": [
                        "长春高新",
                        "生长激素",
                        "净利增长",
                        "产品线布局",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}